Moreover, in vitro and in vivo experiments demonstrated that BMSC‐exo‐miR‐30b‐5p could inhibit EZH2 expression by activating the PI3K/AKT signalling pathway to suppress the progression of NSCLC. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.